Mr. Miskel s qualifications to serve on our Board and chair our Nominating/Governance Committee include his senior executive experience, his involvement in setting strategy for large businesses such as Lilly, Baxter, Baxalta and Shire, his extensive sales and marketing experience, and his knowledge of the healthcare industry and related privacy and cybersecurity issues. His senior roles in the pharmaceutical industry have also provided him with experience navigating complex and changing regulatory environments. Career Highlights Eli Lilly and Company (prior to 2013) Pharmaceutical company General Manager, Lilly Australia and New Zealand Other senior roles Community Involvement B utler University (2021-present) Board of Trustees Medical College of Wisconsin (2018-present) Board of Directors Versiti, Inc. (2017-present) Blood products supply and research company President and Chief Executive Officer Baxter / Baxalta / Shire (2013-2017) Baxalta Incorporated spun off from Baxter International Inc. in 2015 and was acquired by Shire plc in 2016 Global healthcare and pharmaceutical company Head of Immunology (2015-2017) Vice President, Plasma Strategy and New Products, Global BioTherapeutics / U.S. BioScience National Accounts (2013-2015) Age: 51 Director Since: 2020 Public Company Board: 1 Committee Memberships: Nominating/ Governance (Chair) Compensation